Skip to Content

Loncar Cancer Immunotherapy ETF CNCR

Medalist Rating as of | See Loncar Investment Hub

Morningstar’s Analysis CNCR

Will CNCR outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in Loncar Cancer Immunotherapy ETF's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CNCR

  • Current Portfolio Date
  • Equity Holdings 86
  • Bond Holdings 0
  • Other Holdings 3
  • % Assets in Top 10 Holdings 20.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

US DOLLARS

4.71
522,045
Cash and Equivalents
2.76
306,273
Healthcare
2.15
238,719
Healthcare
2.02
223,532
Healthcare
1.92
212,391
Healthcare
1.78
196,913
Healthcare
1.69
187,430
Healthcare
1.64
181,997
Healthcare
1.64
181,172
Healthcare